Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 studyKohei Shitara, Yung‐Jue Bang, Patricio Yañez et al.|The Lancet Oncology|2023Cited by 336
Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.Salah-Eddin Al-Batran, Timo Gaiser, Sylvie Lorenzen et al.|Journal of Clinical Oncology|2022Cited by 96
A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.Salah-Eddin Al-Batran, Thorsten Oliver Goetze, Sylvie Lorenzen et al.|Journal of Clinical Oncology|2023Cited by 13
Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pretreated Patients with Metastatic Lung CancerSalah-Eddin Al-Batran, Eliézer Jäger, Akin Atmaca et al.|Oncology Research and Treatment|2004Cited by 5
A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancerAkin Atmaca, E. Jaeger, Alexander Maurer et al.|Journal of Clinical Oncology|2004Cited by 4